Subscribe to RSS
DOI: 10.1055/s-2006-941487
Effective Treatment of Coprophagia in a Patient with Schizophrenia with the Novel Atypical Antipsychotic Drug Perospirone
A Case ReportPublication History
Received: 15.11.2005
Accepted: 12.1.2006
Publication Date:
23 May 2006 (online)
![](https://www.thieme-connect.de/media/pharmaco/200603/lookinside/thumbnails/10.1055-s-2006-941487-1.jpg)
Here we report on a patient with schizophrenia who suffered from medication-refractory coprophagia. Although there were few cases in which psychotropic medication was effective against coprophagia, we encountered a patient with schizophrenia in whom coprophagia rapidly disappeared after treatment with perospirone, a novel atypical antipsychotic drug of the serotonin-dopamine antagonist (SDA) type. Perospirone has a uniquely high affinity for serotonin-1A receptors, and it could be speculated that perospirone, as a serotonin-1A receptor agonist combined with SDA, may have greater efficacy for treatment-refractory symptoms of schizophrenia. Thus, perospirone is an agent with possible efficacy for medication-refractory schizophrenia.
References
- 1 Bantick R A, Deakin J FW, Grasby P M. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. J Psychopharmacol. 2001; 15 37-46
- 2 Chaturvedi S K. Coprophagia in a schizophrenic patient: case report. Psychopathology. 1988; 21 31-33
- 3 Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M. Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol. 1990; 54 478-481
Ken-Ichi Harada, M.D.
Hokujinkai Ishibashi Hospital
3-7-7, Nagahashi
Otaru
047-8585 Japan
Phone: (81)-134-25-6655
Fax: (81)-11-726-9817
Email: haradak-psy@umin.ac.jp